Skip to main
TVTX
TVTX logo

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 56%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics Inc. is demonstrating strong momentum in its Filspari product, evidenced by a robust increase in new patient starts, which rose 37% quarter-over-quarter in 4Q24. The anticipated regulatory updates and potential expansion into focal segmental glomerulosclerosis (FSGS) signify a substantial market opportunity, projected to reach approximately $521 million by 2030. With the company planning to file a supplemental new drug application for Filspari and improving its probability of success in FSGS significantly, there is a promising outlook for continued growth and revenue enhancement.

Bears say

The analysis highlights significant commercial risks for Travere Therapeutics, particularly regarding its therapy Filspari, which may not achieve consensus estimates for the indications IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Furthermore, 70% of IgAN patients are below the key growth driver metric of 1.5 g/g, indicating a limited patient population that could directly benefit from Filspari. The competitive landscape poses additional challenges, with rival therapies potentially offering superior efficacy or safety profiles, alongside the looming threat of earlier generic competition impacting future revenue forecasts.

Travere Therapeutics (TVTX) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 56% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 16 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.